ScholarLens Back to search
2002•Journal of Attention DisordersRequires access

Editorial

L. Greenhill, Laurence L. Greenhill

Open publisher page 0 citations

Abstract

More than 65 years ago, careful observation revealed that stimulant medication can reduce the disruptive symptoms of hyperkinetic children. Today, a variety of stimulant medications have been marketed, such as preparations including methylphenidate (MPH), dextroamphetamine (DEX), mixed-salts amphetamine (AMP), and pemoline (PEM). These constitute the most widely prescribed psychotropic medications for children, primarily in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). Although this disorder begins in childhood, ADHD is now known to persist into adolescence and adult life, and these individuals are increasingly being prescribed stimulants for this condition. Stimulants are also used for the treatment of narcolepsy, based on controlled studies.

About this research paper

What this paper is about

More than 65 years ago, careful observation revealed that stimulant medication can reduce the disruptive symptoms of hyperkinetic children. Today, a variety of stimulant medications have been marketed, such as preparations including methylphenidate (MPH), dextroamphetamine (DEX), mixed-salts amphetamine (AMP), and pemoline (PEM). These constitute the most widely prescribed psychotropic medications for children, primarily in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). Although this disorder begins in childhood, ADHD is now known to persist into adolescence and adult life, and these individuals are increasingly being prescribed stimulants for this condition. Stimulants are also used for the treatment of narcolepsy, based on controlled studies.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

More than 65 years ago, careful observation revealed that stimulant medication can reduce the disruptive symptoms of hyperkinetic children. Today, a variety of stimulant medications have been marketed, such as preparations including methylphenidate (MPH), dextroamphetamine (DEX), mixed-salts amphetamine (AMP), and pemoline (PEM). These constitute the most widely prescribed psychotropic medications for children, primarily in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). Although this disorder begins in childhood, ADHD is now known to persist into adolescence and adult life, and these individuals are increasingly being prescribed stimulants for this condition. Stimulants are also used for the treatment of narcolepsy, based on controlled studies.

Key concepts: Methylphenidate, Dextroamphetamine, Stimulant, Narcolepsy, Psychology, Psychiatry, Amphetamine, Attention deficit hyperactivity disorder

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Editorial — Research Paper | ScholarLens